Mechanical
thrombectomy (MT) has been established as a standard of care for
patients with acute ischemic stroke for the past five years. However,
the direct benefits of this treatment in patients with baseline
disability remains unclear. This study aims to elucidate the cost impact
of performing MT on patients with moderate-to-severe baseline
disability to work towards an optimized system of care for acute
ischemic stroke. We developed a Markov economic model with a life-time
horizon analysis of costs associated with mechanical thrombectomy in
patients grouped on baseline disability as defined by modified Rankin
Score. Our clinical and economic data is based on an American payer
perspective. Our results identified a marginal cost-effective ratio
(mCER) of $18,835.00 per quality-adjusted life year (QALY) when
mechanical thrombectomy is reserved as a treatment only for patients
with no-to-minimal baseline disability as compared to those with any
level of baseline disability. Our results provide a framework for these
future studies and highlight key sectors that drive cost in the surgical
treatment and life-long care of patients with acute ischemic stroke.
No comments:
Post a Comment